The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Update from the ACR Insurance Subcommittee

Update from the ACR Insurance Subcommittee

March 18, 2022 • By Rebecca Shepherd, MD, MBA, FACR, FACP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The Insurance Subcommittee (ISC) of the ACR Committee on Rheumatologic Care has had an active start to 2022. High priorities have been advocating for changes to burdensome prior authorization requirements and ensuring continued access to physician-administered therapies.

You Might Also Like
  • Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
  • ACR Insurance Subcommittee Chair Encourages Member Engagement
  • The ACR Insurance Subcommittee Advocates for Fair Payer Policies
Also By This Author
  • September Updates from the ACR Insurance Subcommittee

Prior Authorization

Last summer, CVS Caremark made extensive changes to its prior authorization forms for biologic drugs that significantly increased administrative burden on practices. The ACR received many complaints about the changes, chiefly the new criteria around the evaluation of treatment efficacy for continuation of therapy requests. The ISC has been communicating with CVS leaders to relay these concerns and advocate for specific updates that would help alleviate the burden on rheumatology practices. CVS has committed to revising the forms to help address the concerns, and the new version is scheduled to be implemented on April 1.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Physician-Administered Therapies

In late 2021, Blue Cross Blue Shield of South Carolina (BCBS SC) sent letters to patients prescribed intravenous (IV) biologics that also have self-administered formulations (such as abatacept and tocilizumab) informing them that coverage for the infused formulation would be discontinued as of Jan. 1, 2022. After this date, patients would be required to switch to the self-administered formulation upon expiration of their current prior authorization.

The ISC sent a letter to the payer highlighting the differences between the intravenous and self-administered formulations, reaffirming that the treatment decision falls under the physician’s purview and advocating for continued coverage of IV biologics. In follow-up to the letter, we had the opportunity to speak with BCBS SC leaders, who confirmed that IV therapies are still covered under the medical benefit with a valid prior authorization citing clinical justification.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Access in Rheumatology Meeting

If you are interested in learning more about insurance and access issues, join us in Orlando, Fla., on Saturday, April 30, for the Access in Rheumatology meeting. As part of the 2022 ACR Education Exchange, this meeting will bring together ACR/ARP members, partner organizations, payer representatives and other subject-matter experts to discuss coverage and payment issues impacting access to rheumatology care and treatment. We look forward to seeing everyone face to face for this in-person meeting. See the ACR website for additional information and registration.

The ISC exists to help members with issues related to insurance policies and payers. If you would like the ACR’s help regarding payer issues specific to your own practice or if there is a payer policy you think we should be aware of, reach out to [email protected].

Pages: 1 2 | Single Page

Filed Under: American College of Rheumatology, Legislation & Advocacy, Practice Management Tagged With: ACR Insurance Subcommittee (ISC), drug access, insurance advocacy, physician-administered therapy, prior authorization

You Might Also Like:
  • Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
  • ACR Insurance Subcommittee Chair Encourages Member Engagement
  • The ACR Insurance Subcommittee Advocates for Fair Payer Policies
  • ACR Insurance Subcommittee Responds to Payer Policies

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)